Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
October 27th at 5pm Paris Time is 11AM (EDT) October 27th.
There is a plus 6 hrs. difference New York to Barcelona time.
Tred, The only thing I can think of is to have a couple of large easels set behind Dr. Hampel displaying some of Valerie Lynch's paintings that she painted after she was in the first trial and for Pauline Stevens quietly playing a piano for 15 minutes as Dr. Hampel refers to them as RWE ending with a large crescendo when he has finished his presentation. Also he could invite attendees to visit with Ern who all week could be near Dr. Macfarlane's poster.
GLTA and God Bless those afflicted and Dr.Missling's crew.
Yes Viewed tomorrow and all week as well as Saturday morning after Dr Hampel’s presentation.
Dr MacFarlane will have the opportunity to answer many questions in detail with that much exposure.
I think it is much better than a quick 15 minute rushed oral presentation .
Dr. Macfarlane’s poster is up for the entire conference as OFP stared.
This was posted in #168646 a few days ago
“It is good to see that the posters will be available for the entire conference instead of just a single day providing an opportunity for attendees (and media ) to review those of interest they might have missed. “
Quote:
Coffee Breaks and Poster Sessions:
Breaks and poster presentations will be held in the dedicated area across from the auditorium. This year all posters for all the different themes will be presented during the entire conference. Meet our poster presenters during the coffee breaks.
CTAD 2018 Program
Xena, here is the link to the Cantor presentation.
http://wsw.com/webcast/cantor7/avxl/
Power go back and read post # 168646 that you had previously responded to and read the entire post. You should find your answers there. Not sure how you missed it the first time.
Poster presentation:
P91 - A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-Week Trial of ANAVEX®2-73 for the
Treatment of Early Alzheimer’s Disease Together with Precision Medicine Genetic Biomarkers
Stephen Macfarlane, MBBS FRANZCP1
, Michael Kornhauser BPharm1
, Ella Modini BSc1
, Harald Hampel, MD PhD2
, Stephan Toutain MS3
,
Christopher Missling PhD3
1
HammondCare Dementia Centre, NSW, Australia, 2Sorbonne University, Paris, France, 3
Anavex Life Sciences Corp., New York, USA
Coffee Breaks and Poster Sessions:
Breaks and poster presentations will be held in the dedicated area across from the auditorium. This year all posters for all the different themes will be presented during the entire conference. Meet our poster presenters during the coffee breaks.
Yes Tred, he is the presenter of a poster presentation.
P91 - A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-Week Trial of ANAVEX®2-73 for the
Treatment of Early Alzheimer’s Disease Together with Precision Medicine Genetic Biomarkers
Stephen Macfarlane, MBBS FRANZCP1
, Michael Kornhauser BPharm1
, Ella Modini BSc1
, Harald Hampel, MD PhD2
, Stephan Toutain MS3
,
Christopher Missling PhD3
1
HammondCare Dementia Centre, NSW, Australia, 2Sorbonne University, Paris, France, 3
Anavex Life Sciences Corp., New York, USA
I agree with some deal possibly being announced.
Guesses could be around some kind of licensing/partnering deal to be revealed post CTAD...
Quiet period
From Wikipedia, the free encyclopedia
In United States securities law, the quiet period (or waiting period) has "historically [meant], a quiet period of time extended from the time a company files a registration statement with the SEC until SEC staff declared the registration statement effective. During that period, the federal securities laws limited what information a company and related parties can release to the public."[1]
Under the rules of the Securities Act of 1933, as modified June 29, 2005, electronic communications, including electronic road shows and information located on or hyperlinked to an issuer's website are also governed. The rules changes of June 29, 2005, also included various changes which "liberalize permitted offering activity and communications to allow more information" for certain qualifying organizations.
During a Quiet Period, a publicly listed company cannot make any announcements about anything that could cause a normal investor to change their position on the company's stock. Normally, that means the company does not discuss any of the following:
New deals or wins signed in that current quarter.
Announcements about previously sold implementations going live are allowed but must be explicitly described as such.
Management changes
Progress against company goals
Major product or service announcements
Major partnership announcements
Very well stated. There are a couple of things that do enter in my mind however.
I am still puzzled about the 9 million share day that did not affect the share price. I assume the buyer/buyers arranged deals with those funds that had to rid their portfolios of AVXL after being eliminated from the Russell. (per Xena's posited view). Who was/were the buyer/buyers and why? We should get that information in a few weeks.
Is there a possibility of an announcement of one or more licensing or partnerships deals before approval of any of the trials?
It looks like October is going to full of information to be followed up by the November presentation by Dr. Herald Hampel. A lot going on by the end of the year. My guess is that we wont be seeing much tax loss selling.
brichnyc - I believe this is the link referred to.
neiu Tuesday, 09/25/18 07:28:46 AM
Re: TTTav66 post# 166618 0
Post #
166633
of 166649
Thanks T... More to your post
http://www.abc.net.au/7.30/australian-scientists-trial-radical-alzheimers-drug/10304508
Interesting article. Could this be a possible reason that Dr. Missling has been invited to congressional committees as well as other important panels?
https://townhall.com/columnists/mytheosholt/2018/08/17/pharma-is-running-out-of-scapegoats-for-high-drug-prices-n2510612
Love it.
In looking at Dr. Hampel's bio, I think that he needs more experience in the field to broaden his knowledge base of alzheimers unfortunately before we can put much weight on his statements.
Why not wait for P2b/P3 to complete? Then you would have more conclusive scientific information to support your case. Should only be about 2 years away..
McMac, wasn't there a group that organized and demanded a meeting with a congressional committee and obtained subsequent approval to have a drug released. I don't recall the disease Duchene's seems to stick in my mind.
Maybe you and others on this board that have the verbal skills could start putting pressure on the Alzheimers Association to organize a group of those families affected and request a similar meeting. Maybe a group effort to "construct" a letter that could be made available for the rest of us to send to our Senators and representatives and local Alzheimers groups.
That was one of my thoughts but as F1ash pointed out on 7/3 Anavex was under the agreement with LPC which had a daily restriction and the agreement with Cantor Fitzgerald was not registered until 7/6.
However, it sticks in my mind that there was some stipulations in te LPC agreement that allowed for accelerated selling. I didn't research it now but this seems to be in the deep recesses of my old feeble mind.
Thank you. It is just puzzling to me. The rough average daily volume was about 750,000 shares leading up to this. The price share closed at $2.66 on 7/2 and opened at $3.21 on 7/3 then ran up to $3.82 on the day.
I see a similar pattern the beginning of June where the average daily volume was less than 300,000 shares. On June 1st AVXL closed at $2.87 on June 4th it opened at $2.92 and then ran up to $3.78 on 4,572,467 shares.
I guess it is possible that some institutions are adding at the beginning of reporting periods and the interest is increasing and July being a more logical start of a fiscal quarter that created this large volume.
My assumption is that there were 9,000,000 shares sold and bought on 7/3.
Thank you F1ash. I just got back to my computer. I was aware of those events but very curious as to where/who had 20% of the less than 45,000,000 outstanding shares to transfer(?) in one transaction. The only thing I could see is the possibility that Anavex utilized part of their remaining 100,000,000 shares authorized to raise cash and it was all picked up by one entity that doesn't have to report over 5% holding until the end of this quarter.
This was all cleverly done at the very beginning of the 3rd quarter and is not required to be filed with the SEC for three months. It is very apparent that it wasn't Biogen (IMO). (Maybe it was the Sovereign Nation Of Australia since they seem to be the most concerned about helping alzheimers patients. )
What is/was the consensus of the 9,000,000 shares traded on 7/3?
I don't recall that there was a lot of discussion about this. I was travelling at the time and might have missed it.
Is this near the same time frame when Dr. Missling said 'the share price will take care of it self when the news hits' (to paraphrase)?
Example of patent protection information for A2-73.
Here is Jimmy's excellent post from 8/16/17.
jimmy667 Wednesday, 08/16/17 12:07:02 PM
Re: Amatuer17 post# 115707 0
Post #
115752
of 157953
A2-73 IP is 100% locked down until the 2030s.
Again for those that would ignore facts:
Anavex has a complete portfolio of patent and patents pending 100% protecting A2-73 from generics until the 2030s here is just one example:
ABSTRACT
Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2- diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).
CLAIMS (OCR text may contain errors)
CLAIMS What is claimed is:
1. A crystalline form of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride characterized by the PXRD pattern shown in FIG. 1, FIG. 4, or FIG. 8.
2. The crystalline form of claim 1, further characterized by the FTIR spectrum shown in FIG. 5 or FIG. 9.
3. The crystalline form of claim 1, further characterized by the ^-NMR spectrum shown in FIG. 6 or FIG. 10.
4. The crystalline form of claim 1, further characterized by the particle shapes depicted in FIG. 2, FIG. 3, FIG. 7 or FIG. 11.
5. The crystalline form of claim 1, further characterized by the particle sizes depicted in FIG. 2, FIG. 3, FIG. 7 or FIG. 11.
6. The crystalline form of claim 1, wherein the habit is plate-like.
7. The crystalline form of claim 1, wherein the habit is needle-like.
The crystalline form of claim 1, wherein the habit is lath
9. A method of making the crystalline form of claim 1, wherein the method uses a supercritical fluid (SCF) technique.
10. A dosage form comprising a therapeutically neuroprotective amount of the crystalline form of claim 1.
11. A pharmaceutical composition for the treatment of Alzheimer's disease comprising a therapeutically effective amount of the crystalline form of any of claims 1-8.
12. A method of treating Alzheimer's disease in a subject comprising administering to the subject a therapeutically effective amount of the crystalline form of any of claims 1-8.
13. Crystalline Form I of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride characterized by the PXRD pattern shown in FIG. 1.
14. The crystalline Form I according to claim 13, characterized by the particle shapes as depicted in FIG. 2.
15. The crystalline Form I according to claim 13, characterized by the particle shapes as depicted in FIG. 3.
16. The crystalline Form I according to claim 13, characterized by the particle sizes as depicted in FIG. 2.
17. The crystalline Form I according to claim 13, characterized by the particle sizes as depicted in FIG. 3.
18. The crystalline form of claim 13, wherein the habit is plate-like.
19. A method of making the crystalline form of any of claims 13-18, wherein the method uses a supercritical fluid (SCF) technique.
20. A dosage form comprising a therapeutically neuroprotective amount of the crystalline form of any of claims 13-18.
21. A pharmaceutical composition for the treatment of Alzheimer's disease comprising a therapeutically effective amount of the crystalline form of any of claims 13-18.
22. A method of treating Alzheimer's disease in a subject comprising administering to the subject a therapeutically effective amount of the crystalline form of any of claims 13-18.
23. Crystalline Form II of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride characterized by the PXRD pattern shown in FIG. 4.
24. Crystalline Form II of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride characterized by the FTIR spectrum shown in FIG. 5.
25. Crystalline Form II of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride characterized by the ^-NMR spectrum shown in FIG. 6.
26. The crystalline Form II according to any of claims 23-25, characterized by particle shapes as depicted in FIG. 7.
27. The crystalline Form II according to any of claims 23-25, characterized by particle sizes as depicted in FIG. 7.
28. The crystalline Form II of any of claims 23-25, wherein the habit is plate-like.
29. A method of making the crystalline Form II of any of claims 23-28, wherein the method uses a supercritical fluid (SCF) technique.
30. A dosage form comprising a therapeutically neuroprotective amount of the crystalline Form II of any of claims 23-28.
31. A pharmaceutical composition for the treatment of Alzheimer's disease comprising a therapeutically effective amount of the crystalline Form II of any of claims 23-28.
32. A method of treating Alzheimer's disease in a subject comprising administering to the subject a therapeutically effective amount of the crystalline Form II of any of claims 23-28.
33. Crystalline Form III of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride characterized by the PXRD pattern shown in FIG. 8.
34. Crystalline Form III of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride characterized by the FTIR spectrum shown in FIG. 9.
35. Crystalline Form III of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride characterized by the ^-NMR spectrum shown in FIG. 10.
36. The crystalline Form III according to any of claims 33-35, characterized by particle shapes as depicted in FIG. 11.
37. The crystalline Form III according to any of claims 33-35, characterized by particle sizes as depicted in FIG. 11.
38. The crystalline Form III of any of claims 33-35, wherein the habit is lath-like.
39. A method of making the crystalline Form III of any of claims 33-38, wherein the method uses a supercritical fluid (SCF) technique.
40. A dosage form comprising a therapeutically neuroprotective amount of the crystalline Form III of any of claims 33-38.
41. A pharmaceutical composition for the treatment of Alzheimer's disease comprising a therapeutically effective amount of the crystalline Form III of any of claims 33-38.
42. A method of treating Alzheimer's disease in a subject comprising administering to the subject a therapeutically effective amount of the crystalline Form III of any of claims 33-38.
43. The metabolite ANAVEX19-144 characterized by the PXRD pattern shown in FIG. 12.
44. The metabolite ANAVEX19-144 characterized by the DSC-TGA data shown in FIG. 13.
45. The metabolite ANAVEX19-144 characterized by the FTIR spectrum shown in FIG. 14.
46. The metabolite ANAVEX19-144 of any of claims 43-45 characterized by particle shapes as depicted in FIG. 15.
47. The metabolite ANAVEX19-144 of any of claims 43-45 characterized by particle sizes as depicted in FIG. 15.
48. The metabolite ANAVEX19-144 of any of claims 43-45, wherein the habit is needle-like.
49. A method of making the metabolite ANAVEX19-144 of any of claims 43-48, wherein the method uses a supercritical fluid (SCF) technique.
50. A dosage form comprising a therapeutically neuroprotective amount of the metabolite ANAVEX19-144 of any of claims 43-48.
51. A pharmaceutical composition for the treatment of Alzheimer's disease comprising a therapeutically effective amount of the metabolite ANAVEX19-144 of any of claims 43-48.
52. A method of treating Alzheimer's disease in a subject comprising administering to the subject a therapeutically effective amount of the metabolite ANAVEX19-144 of any of claims 43-48.
53. The metabolite ANAVEX19-144 characterized by the PXRD pattern shown in FIG. 17.
54. The metabolite ANAVEX19-144 characterized by the DSC-TGA data shown in FIG. 18.
55. The metabolite ANAVEX19-144 of any of claims 53-54 characterized by particle shapes as depicted in FIG. 16.
56. The metabolite ANAVEX19-144 of any of claims 53-54 characterized by particle sizes as depicted in FIG. 16.
57. A method of making the metabolite ANAVEX19-144 of any of claims 53-56, wherein the method uses a supercritical fluid (SCF) technique.
58. A dosage form comprising a therapeutically neuroprotective amount of the metabolite ANAVEX19-144 of any of claims 53-56.
59. A pharmaceutical composition for the treatment of Alzheimer's disease comprising a therapeutically effective amount of the metabolite ANAVEX19-144 of any of claims 53-56.
60. A method of treating Alzheimer's disease in a subject comprising administering to the subject a therapeutically effective amount of the metabolite ANAVEX19-144 of any of claims 53-56.
DESCRIPTION (OCR text may contain errors)
CRYSTAL FORMS OF TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-3- FURANM ETHAN AMINE HYDROCHLORIDE, PROCESSES OF MAKING SUCH
FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS
FIELD
[0001] The present disclosure is directed to crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine
hydrochloride, as well as compositions, processes of preparation, and uses thereof.
BACKGROUND
[0002] Because improved drug formulations showing, for example, better bioavailability or better stability are consistently sought, there is an ongoing need for more fully characterized, new, polymorphic and derivative forms of drug molecules. Characterization of tetra hydro -N,N - dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, and crystalline polymorphs and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride are described herein toward this end.
SUMMARY OF THE PRESENT DISCLOSURE
[0003] The present disclosure comprises crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride characterized by the PXRD pattern shown in FIG. 1, FIG. 4, or FIG. 8. The crystalline forms are further characterized by the FTIR spectrum shown in FIG. 5 or FIG. 9. The crystalline forms are further characterized by the H-NMR spectrum shown in FIG. 6 or FIG. 10. The crystalline forms are further characterized by the particle shapes depicted in FIG. 2, FIG. 3, FIG. 7 or FIG. 11. The crystalline forms are further characterized by the particle sizes depicted in FIG. 2, FIG. 3, FIG. 7 or FIG. 11. The crystalline forms can have a plate-like habit. The crystalline forms can also have a needle-like habit. The crystalline forms can have a lath-like habit. Further included, is a method of making the crystalline forms using a supercritical fluid (SCF) technique. Further included is a dosage form comprising a therapeutically neuroprotective amount of the crystalline forms. Further included is a pharmaceutical composition for the treatment of Alzheimer's disease comprising a therapeutically effective amount of the crystalline forms. Further included is a method of treating Alzheimer's disease in a subject comprising administering to the subject a therapeutically effective amount of the crystalline forms.
[0004] The present disclosure also comprises crystalline Form I of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride characterized by the PXRD pattern shown in FIG. 1. The crystalline Form I according is also characterized by the particle shapes as depicted in FIG. 2. The crystalline Form I is also characterized by the particle shapes as depicted in FIG. 3. The crystalline Form I is also characterized by the particle sizes as depicted in FIG. 2. The crystalline Form I is also characterized by the particle sizes as depicted in FIG. 3. Crystalline Form I is also characterized by a plate-like habit. Further included is a method of making crystalline Form I using a supercritical fluid (SCF) technique. Further included is a dosage form comprising a therapeutically neuroprotective amount of crystalline Form I. Further included is a pharmaceutical composition for the treatment of Alzheimer's disease comprising a therapeutically effective amount of crystalline Form I. Further included is a method of treating Alzheimer's disease in a subject comprising administering to the subject a therapeutically effective amount of the crystalline Form I.
[0005] The present disclosure also comprises crystalline Form II of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride characterized by the PXRD pattern shown in FIG. 4. Crystalline Form II is also characterized by the FTIR spectrum shown in FIG. 5. Crystalline Form II is also characterized by the ^-NMR spectrum shown in FIG. 6. Crystalline Form II is also characterized by particle shapes as depicted in FIG. 7. Crystalline Form II is also characterized by particle sizes as depicted in FIG. 7. Crystalline Form II can also have a plate-like habit. Further included is a method of making crystalline Form II using a supercritical fluid (SCF) technique. Further included is a dosage form comprising a therapeutically neuroprotective amount of crystalline Form
II. Further included is a pharmaceutical composition for the treatment of Alzheimer's disease comprising a therapeutically effective amount of crystalline Form II. Further included is a method of treating Alzheimer's disease in a subject comprising administering to the subject a therapeutically effective amount of crystalline Form II.
[0006] The present disclosure also comprises crystalline Form III of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride characterized by the PXRD pattern shown in FIG. 8. Crystalline Form III is also characterized by the FTIR spectrum shown in FIG. 9. Crystalline Form III is also characterized by the ^-NMR spectrum shown in FIG. 10. Crystalline Form III is also characterized by particle shapes as depicted in FIG. 11. Crystalline Form III is also characterized by particle sizes as depicted in FIG. 11. Crystalline Form III can also have a lath-like habit. Further included is a method of making crystalline Form III using a supercritical fluid (SCF) technique. Further included is a dosage form comprising a therapeutically neuroprotective amount of crystalline Form
III. Further included is a pharmaceutical composition for the treatment of Alzheimer's disease comprising a therapeutically effective amount of crystalline Form III. Further included is a method of treating Alzheimer's disease in a subject comprising administering to the subject a therapeutically effective amount of crystalline Form III.
[0007] The present disclosure also comprises metabolite ANAVEX19- 144 characterized by the PXRD pattern shown in FIG. 12. Metabolite ANAVEX19-144 is also characterized by the DSC-TGA data shown in FIG. 13. Metabolite ANAVEX19-144 is also characterized by the FTIR spectrum shown in FIG. 14. Metabolite ANAVEX19-144 can also be characterized by particle shapes as depicted in FIG. 15. Metabolite ANAVEX19-144 can also be characterized by particle sizes as depicted in FIG. 15. Metabolite ANAVEX19-144 can also have a needle-like habit. Further included is a method of making the metabolite ANAVEX19-144 using a supercritical fluid (SCF) technique. Further included is a dosage form comprising a therapeutically neuroprotective amount of the metabolite ANAVEX19-144. Further included is a pharmaceutical composition for the treatment of Alzheimer's disease comprising a therapeutically effective amount of the metabolite ANAVEX19-144. Further included is a method of treating Alzheimer's disease in a subject comprising administering to the subject a therapeutically effective amount of the metabolite ANAVEX19-144.
[0008] The present disclosure also comprises metabolite ANAVEX19- 144 characterized by the PXRD pattern shown in FIG. 17. Metabolite ANAVEX19-144 is also characterized by the DSC-TGA data shown in FIG. 18. Metabolite ANAVEX19-144 can also be characterized by particle shapes as depicted in FIG. 16. Metabolite ANAVEX19-144 can also be characterized by particle sizes as depicted in FIG. 16. Further included is a method of making the metabolite ANAVEX19-144 using a supercritical fluid (SCF) technique. Further included is a dosage form comprising a therapeutically neuroprotective amount of metabolite ANAVEX19-144. Further included is a pharmaceutical composition for the treatment of Alzheimer's disease comprising a therapeutically effective amount of metabolite ANAVEX19-144. Further included is a method of treating Alzheimer's disease in a subject comprising administering to the subject a therapeutically effective amount of metabolite ANAVEX19-144.
BRIEF DESCRIPTION OF THE DRAWINGS
[0009] In order to describe the manner in which the advantages and features of the disclosure can be obtained, reference is made to embodiments thereof which are illustrated in the appended drawings. Understanding that these drawings depict only exemplary embodiments of the disclosure and are not therefore to be considered to be limiting of its scope, the principles herein are described and explained with additional specificity and detail through the use of the accompanying drawings in which :
[0010] FIG. 1 depicts a powder X-ray diffraction (PXRD) pattern characteristic of polymorph Form I of tetrahydro-N,N-dimethyl-2,2- diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73);
[0011] FIG. 2 depicts scanning electron microscope (SEM) micrographs demonstrating the size and morphology of particles of polymorph Form 1 of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride (ANAVEX2-73) produced using acetonitrile as the solvent in the supercritical fluid process;
[0012] FIG. 3 depicts SEM micrographs demonstrating the size and morphology of particles of polymorph Form 1 of tetrahydro-N,N-dimethyl-
2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) produced using ethanol as the solvent in the supercritical fluid process;
[0013] FIG. 4 depicts a PXRD pattern characteristic of polymorph
Form II of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73); [0014] FIG. 5 depicts a fourier transform infrared (FTIR) spectrum characteristic of polymorph Form II of tetrahydro-N,N-dimethyl-2,2- diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73);
[0015] FIG. 6 depicts a proton nuclear magnetic resonance ^H-NMR) spectrum characteristic of polymorph Form II of tetrahydro-N,N-dimethyl-
2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73);
[0016] FIG. 7 depicts SEM micrographs demonstrating the size and morphology of particles of polymorph Form II of tetra hydro -N,N - dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-
73);
[0017] FIG. 8 depicts a PXRD pattern characteristic of polymorph Form III of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73);
[0018] FIG. 9 depicts an FTIR spectrum characteristic of polymorph Form III of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73);
[0019] FIG. 10 depicts a ^-NMR spectrum characteristic of polymorph Form III of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73);
[0020] FIG. 11 depicts SEM micrographs demonstrating the size and morphology of particles of polymorph Form III of tetra hydro- N,N - dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2- 73);
[0021] FIG. 12 depicts a PXRD pattern characteristic of metabolite ANAVEX19-144 produced using ethanol as the solvent in the supercritical fluid process;
[0022] FIG. 13 depicts DSC-TGA data characteristic of metabolite ANAVEX19-144 produced using ethanol as the solvent in the supercritical fluid process; [0023] FIG. 14 depicts a FTIR spectrum characteristic of metabolite ANAVEX19-144 produced using ethanol as the solvent in the supercritical fluid process;
[0024] FIG. 15 depicts SEM micrographs demonstrating the size and morphology of particles of metabolite ANAVEX19-144 produced using ethanol as the solvent in the supercritical fluid process;
[0025] FIG. 16 depicts SEM micrographs demonstrating the size and morphology of particles of metabolite ANAVEX19-144 produced using dichloromethane as the solvent in the supercritical fluid process;
[0026] FIG. 17 depicts a PXRD pattern characteristic of metabolite ANAVEX19-144 produced using dichloromethane as the solvent in the supercritical fluid process; and
[0027] FIG. 18 depicts DSC-TGA data characteristic of metabolite ANAVEX19-144 produced using dichloromethane as the solvent in the supercritical fluid process.
DETAILED DESCRIPTION
[0028] Various embodiments of the disclosure are discussed in detail below. While specific implementations are discussed, it should be understood that this is done for illustration purposes only. A person skilled in the relevant art will recognize that other components and configurations may be used without parting from the spirit and scope of the disclosure.
[0029] It should be understood at the outset that although illustrative implementations of one or more embodiments are illustrated below, the disclosed method may be implemented using any number of techniques. The disclosure should in no way be limited to the illustrative implementations, drawings, and techniques illustrated herein, but may be modified within the scope of the appended claims along with their full scope of equivalents.
[0030] In the following discussion and in the claims, the terms "including" and "comprising" are used in an open-ended fashion, and thus should be interpreted to mean "including, but not limited to The various characteristics described in more detail below, will be readily apparent to those skilled in the art with the aid of this disclosure upon reading the following detailed description, and by referring to the accompanying drawings.
[0031] The present disclosure relates to tetrahydro-N,N-dimethyl-2,2- diphenyl-3-furanmethanamine hydrochloride, also referred to as ANAVEX2-73 :
Figure imgf000009_0001
[0032] It has been reported that ANAVEX2-73 shows neuroprotective potential against amyloid toxicity in mice. In particular, ANAVEX2-73 has been reported as attenuating oxidative stress, caspases induction, cellular loss and learning and memory deficits observed in mice one week after the i.c.v. injection of an oligomeric preparation of amyloid 625-35 peptide (?ß25-35) . See J. Psvchopharmacol. 25(8), 1101-1117 (2011). More recently, it has been reported that ANAVEX2-73 blocked the ?ß25-35- induced P-Akt decrease and P-GSK-3 increase, indicating activation at the PI3K neuroprotective pathway. See Neuropsvchopharmacoloav 38, 1706-1723 (2013). In the dose-range tested, ANAVEX2-73 attenuated the hyperphosphorylation of Tau on physiological epitopes (AT-8 antibody clone) and on pathological epitopes (AT-100 clone). ANAVEX2-73 also has been reported to decrease the A 25-35-induced endogenous ?ß?-42 seeding.
[0033] Reference is made to U.S. Patent Publication No. 2014/0296211 entitled "ANAVEX2-73 AND CERTAIN
ANTICHOLINESTERASE INHIBITORS COMPOSITION AND METHOD FOR NEUROPROTECTION," to Vamvakides et al., filed July 12, 2013; USSN 62/065,833 entitled "A19-144, A2-73 AND CERTAIN ANTICHOLINESTERASE INHIBITOR COMPOSITIONS AND METHOD FOR ANTI-SEIZURE THERAPY," filed October 20, 2014; U.S. Patent application entitled "ANAVEX2-73 FOR THE TREATMENT OF ALZHEIMER'S DISEASE" and filed on date even herewith; U.S. Patent application entitled "ENANTIOMERS OF A2-73, ANALOGUES, AND SIGMA AGONIST ACTIVITY" and filed on date even herewith. The teaching of these applications and publications and all references cited herein are incorporated by reference in their entirety.
[0034] The present disclosure, provides a crystalline polymorph (Form I) of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride , characterized by PXRD and other data provided herein.
[0035] The present disclosure provides another crystalline polymorph (Form II) of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride characterized by the PXRD and other data provided herein.
[0036] The present disclosure further provides another crystalline polymorph (Form III) of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride characterized by the PXRD and other data provided herein.
[0037] The present disclosure also provides a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine
hydrochloride, referred to as ANAVEX19-144, characterized by the PXRD and other data provided herein and having the structure:
Figure imgf000011_0001
[0038] The present disclosure further provides use of the polymorphs and metabolite material in the treatment of Alzheimer's disease.
[0039] Tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) was characterized by powder X-ray diffraction (PXRD), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), fourier transform infrared (FTIR) spectroscopy, proton nuclear magnetic resonance ^H-NMR) and scanning electron microscopy (SEM), as detailed in FIGS. 1-15.
[0040] The present disclosure further provides processes of preparing the polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride (ANAVEX2-73). In one embodiment, the polymorphic forms, disclosed herein, can be prepared by a supercritical fluid (SCF) anti-solvent process. In an embodiment, the anti-solvent is a supercritical fluid, although in some embodiments near- critical fluids may also be suitable. A "supercritical fluid" is a fluid at or above its critical pressure (Pc) and critical temperature (Tc) simultaneously. In practice, the pressure of the fluid is likely to be in the range between 1.01 and 7.0 of its critical pressure, and its temperature in the range between 1.01 and 4.0 of its critical temperature (in Kelvin). However, some fluids (e.g., helium and neon) have particularly low critical pressures and temperatures, 10 and may need to be used under operating conditions well in excess of those critical values, such as up to 200 times the relevant critical value. The term "near-critical fluid" encompasses both high pressure liquids, which are fluids at or above their critical pressure but below (although preferably close to) their critical temperature, and dense vapors, which are fluids at or above their critical 15 temperature but below (although preferably close to) their critical pressure. By way of example, a high pressure liquid might have a pressure between about 1.01 and 7 times its Pc, and a temperature between about 0.5 and 0.99 times its Tc. A dense vapor might, correspondingly, have a pressure between about 0.5 and 0.99 times its Pc, and a temperature between about 1.01 and 4 times its Tc.
[0041] Suitably, the anti-solvent and solution may be introduced into a precipitation chamber via respective passages with respective outlets, the outlets being arranged relative to one another such that anti-solvent introduced through a first passage and solution introduced through a second passage both enter the precipitation chamber at substantially the same point, which is substantially the point at which the anti-solvent and solution meet. To provide for good levels of mixing and dispersion, the anti-solvent and the solution may, for example, be co-fed into a precipitation chamber via a nozzle having co-axial passages which terminate adjacent to one another. Alternatively, one or more streams of the antisolvent may be arranged to impinge on a stream of the solution to provide good levels of mixing and dispersion. However, other mixing architectures are also possible. Examples of suitable apparatus are known, inter alia, from WO-30 95/01221, WO-96/00610, WO-98/36825, WO-99/44733, WO-99/59710, WO-01/03821, and WO-03/008082, which are incorporated herein by reference.
[0042] According to the present disclosure, new crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) were prepared by a supercritical fluid (SCF) process. The basic process involved preparing a solution of tetrahydro-N,N-dimethyl- 2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) in a suitable solvent, such as acetonitrile or ethanol, and introducing the solution to an SCF environment, typically supercritical CO2, in a pressure vessel. The supercritical CO2 acted as a powerful antisolvent allowing particles to be rapidly precipitated. Different polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) were produced by manipulating SCF process parameters, including the solvent used, flow rate, pressure, and temperature. Additionally, manipulation of SCF process parameters determined the size, morphology, and habit of crystalline particles produced by the SCF process.
[0043] The SCF process parameters used to produce the three polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride (ANAVEX2-73), Forms I-III, are provided in Tables 1-3. As shown in Table 1, crystalline Form I was produced by placing the ANAVEX2-73 starting material in a solvent of acetonitrile or ethanol and processed by the supercritical fluid technique. The resulting particle shape differed depending upon the solvent. The particle shape for the crystalline Form I produced using acetonitrile solvent was plate-like. As used herein, the term "plate-like" refers to a flat particle of similar length and width. The particle shape for the crystalline Form I produced using ethanol solvent was a conglomerate. As used herein, the term "conglomerate" refers to a mixture of two or more types of particle shapes. The resulting material was characterized by PXRD and SEM. The PXRD for crystalline Form I of ANAVEX2-73 is shown in FIG. 1. SEM micrographs showing the particle size and morphology of crystalline Form I are shown in FIGs. 2-3. FIG. 2 shows the particle size and morphology of crystalline Form I produced using acetonitrile solvent (plate-like morphology). FIG. 3 shows the particle size and morphology of crystalline Form I produced using ethanol as the solvent (conglomerate morphology).
[0044] As shown in Table 2, crystalline Form II was produced by placing the ANAVEX2-73 starting material in a solvent of acetonitrile, 1 : 9 v/v trifluoroethanol + ethanol, 1 : 1 v/v acetone + ethanol, or 3-methyl-l- butanol, and processed by the supercritical fluid technique. In all cases, crystalline Form II was characterized by a plate-like habit. The resulting material was characterized by PXRD and SEM . The PXRD for crystalline Form II of ANAVEX2-73 is shown in FIG. 4. Crystalline Form II is further characterized by the FTIR spectrum shown in FIG. 5 and the ^-NMR shown in FIG. 6. SEM micrographs showing the particle size and morphology of crystalline Form II are shown in FIG. 7.
[0045] As shown in Table 3, crystalline Form III was produced by placing the ANAVEX2-73 starting material in a solvent of ethanol or 1 : 9 v/v trifluoroethanol + ethanol and processed by the supercritical fluid technique. In all cases, crystalline Form III was characterized by a lathlike habit. As used herein, "lath-like" refers to a long, thin blade-like particle. The resulting material was characterized by PXRD and SEM . The PXRD for crystalline Form III of ANAVEX2-73 is shown in FIG. 8. Crystalline Form III is further characterized by the FTIR spectrum shown in FIG. 9 and the ^-NMR shown in FIG. 10. SEM micrographs showing the particle size and morphology of crystalline Form III are shown in FIG. 11.
Kentucky - Following is a copy of the World Wide Patent Application for the process and composition of A2-73 and it's metabolite A19-144.
WIPO logo
Mobile | Deutsch | Español | Français | ??? | ??? | Português | ??????? | ?? | ??????? |
PATENTSCOPE
Search International and National Patent Collections
World Intellectual Property Organization
Search
Home IP Services PATENTSCOPE
? ? ? maximize
Machine translation
29. (WO2017013498) CRYSTAL FORMS OF TETRA-HYDRO-N, N-DIMETHYL-2, 2-DIPHENYL-3-FURANMETHANAMINE HYDROCHLORIDE, PROCESSES FOR MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS
PCT Biblio. Data
Description
Claims
National Phase
Notices
Drawings
Documents
Latest bibliographic data on file with the International Bureau
PermaLink
PermaLink
Bookmark
Pub. No.: WO/2017/013498 International Application No.: PCT/IB2016/001181
Publication Date: 26.01.2017 International Filing Date: 19.07.2016
IPC:
C07D 307/14 (2006.01), A61K 31/341 (2006.01), A61P 25/28 (2006.01)
Applicants: ANAVEX LIFE SCIENCES CORP. [--/US]; 51 West 52nd Street, 7th Floor New York, NY 10019 (US)
Inventors: YORK, Peter; (GB).
LEONARD, Lucy, Anne; (GB).
LEDGER, Daniel, Mark; (GB).
DAINTREE, Linda, Sharon; (GB)
Agent: SAUNDERS, Thomas, M.; POLSINELLI PC 100 Cambridge Street, Suite 2101 Boston, MA 02114 (US)
Priority Data:
62/195,486 22.07.2015 US
Title (EN) CRYSTAL FORMS OF TETRA-HYDRO-N, N-DIMETHYL-2, 2-DIPHENYL-3-FURANMETHANAMINE HYDROCHLORIDE, PROCESSES FOR MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS
(FR) FORMES CRISTALLINES DU CHLORHYDRATE DE TÉTRA-HYDRO-N,N-DIMÉTHYL-2,2-DIPHÉNYL-3-FURANE-MÉTHANAMINE, PROCÉDÉS DE PRÉPARATION DESDITES FORMES, ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
Abstract: front page image
(EN)Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2- diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).
(FR)Cette invention décrit et caractérise des formes polymorphes du chlorhydrate de tétrahydro-N,N-diméthyl-2,2-diphényl-3-furane-méthanamine (ANAVEX2-73) et d'un métabolite du chlorhydrate de tétrahydro-N,N-diméthyl-2,2-diphényl-3-furane-méthanamine (ANAVEX2-73). Des compositions et une méthode destinée à traiter la maladie d'Alzheimer qui comprennent les formes polymorphes et le métabolite du chlorhydrate de tétrahydro-N,N-diméthyl-2,2-diphényl-3-furane-méthanamine (ANAVEX2-73) sont en outre décrites.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)
Also from a Polarbear77's post#120449
[i
]Because they've contracted with a world-class team of international patent attorneys to painstakingly document and protect its IP in a wide range of indications and chemical formulations during a process that must have utilized a tremendous amount of time and Company resources. Why in heavens would they waste everyone's time and money if the endeavor was fruitless?
Trader that is a thought I had also, although MS would not be discussed at this conference however.
There may be some announcement? Just thoughts.
Thank you TTT for relating your find of this scheduling. I like the AVXL is presenting before BIO.
Good work Bio, It looks like the AAIC Committee has had enough time to analyze the presentations and make the decision to be sure the attendees receive the maximum information at the conference.
Irish- thank you for posting this article. It is most encouraging for future development of stem cell science.
What could be left for a possible "Late Breaking Presentation" ? ( A joint presentation with Biogen discussing MS and a partnership agreement ???)
Bio- I would assume that Biogen would not have input as to when they present. It should be up to the AAIC committee (IMO) to schedule unless AAIC can be influenced like the FDA.
If both Anavex and Biogen have Late Breaking Presentations the committee would have the presentations in advance to assess. I would think it is the committe's responsibility to schedule so that the conference attendees obtain the maximum benefit.
Very nice Basparks.
Great initiative !
Add potential veterinary use of our drugs to human use to arrive at a future share price.
Here are a couple of statements made by Falconer in his excellent post #116767.
Anavex Will Be Bigger Than Presently Envisioned
[I've also pondered agricultural and veterinary applications for Anavex technologies. Utterly gigantic. By mass, more antibiotics in orders of magnitude are sold and used for animals than humans.]
Market size and forecast
The global veterinary drug market is predicted to flourish significantly at a CAGR of 6.8% over the forecast period i.e. 2016-2023. Moreover, the market of veterinary drug market accounted for USD 25.3 Billion in 2015 and the market is further anticipated to garner USD 49.8 Billion by 2023.
The sleep disorder market will be huge on its own. If I recall correctly 8 out of 8 in the trial that experienced insomnia obtained complete relief.
Also I recall discussion about the potential use in the veterinarian market a couple years ago. Can someone come up with an estimate what that could be in the future?
I am not touring but I am an old guy with arthritis out In a very large vegetable garden and on my iPhone otherwise I would try to find those old posts.
Basparks-You are probably correct. I believe that the 19% was an arguably verifiable low number based on reported results from the trial.
It would be interesting to know more about the patients that Dadof's contact referred to in this correspondence.
dadofmarcmax Wednesday, 05/23/18 12:12:15 PM
Re: Fireman02360 post# 150726 0
Post #
150730
of 150865
I have a very good friend who is a behavioral neurologist in Sydney. She has first hand knowledge of some of the 2-73 patients and how they have been doing.
Australia will likely approve 2-73 BEFORE the US does and if so, get ready for fireworks (according to her).
her opinion only and my post is to convey her opinion.[/
A starting guesstimate might be the six "super responders" out of the 32 in the P2 trial or 19%.
Here is a copy of my previous post regarding funding. Specifically the last parts regarding Australia's Alfred Group.
https://www.alfredhealth.org.au/contents/.../AlfredHealth-AnnualReport-2015-16.pdf
drv17 Member Level Sunday, 03/05/17 02:38:47 PM
Re: biotechrocks post# 94248 0
Post #
94272
of 150949
I don't know why the funding question keeps arising. Dr. Missling has never misled us yet to my knowledge. He has a very strong Board of Directors that I would assume would not jeopardise their reputations by allowing him to mislead.
Perhaps by different ones bringing this question up is just a little FUD or soft bashing.
Here are some points presented numerous times on this board regarding funding.
From The Wall Street Transcripts interview :
Dr. Missling's answer to funding.
TWST: Do you have the financing you need to get through the development of ANAVEX 2-73 at this current stage?
Dr. Missling: Yes, we believe that sufficient financing in place and also because we are working with several foundations on specific diseases like the Michael J. Fox Foundation that has supported us very strongly for exploring ANAVEX 2-73 in a pre-clinical study of Parkinson’s disease, for which positive data was recently reported on September 22nd. And we also received support from the Rettsyndrome.org foundation, which also supported exploring ANAVEX 2-73 in a pre-clinical study in Rett syndrome, a rare disease for which Anavex received FDA orphan designation this year. We might continue these collaborations if the data continues to be promising.
Filed with SEC 10/21/16 This is superb Media coverage,
The Wall Street Transcript is a completely unique resource for investors and business researchers.
Over 20,000 CEO, Equity Analyst and Money Managers
Filed with the SEC.
EX-99.1 2 s104371_ex99-1.htm EXHIBIT 99-1
Exhibit 99.1
Christopher U. Missling, MS, PhD, MBA, President and CEO of Anavex Life Sciences Corp.
Australia information:
Funding? MacFarlane does the research at Caufield Hospital a unit of the Alfred Group in Australia. Here are some excerpts from Alfred Group's Annual Report 2015-16 published August 2016. This indicates that a great deal of funding comes from partnerships.
(Page 4 - Alfred Group annual Report 2015-16)
Chairperson and Chief Executive’s Year in Review (continued)
Discovering the next generation of care Partnerships continued to underpin significant research developments that informed clinical practice in Australia and overseas. Researchers from The Alfred answered the long-held debate over whether aspirin should be stopped before coronary artery surgery. The results of the 10-year international study showed no increased risk of surgical bleeding or need for blood transfusion associated with asprin use. Scientists from The Alfred and Monash University made a breakthrough in targeting aggressive blood cancers through combination therapy, giving hope to people suffering from Acute Myeloid Leukaemia. At our Caulfield campus, early research results from the international drug trial of Anavex 2-73, which aims to address the symptoms of dementia, were positive. Also significant was the announcement of PrEPX, a new public health research study supported by Alfred Health, the Victorian Government and the Victorian AIDS Council. This study will expand access to pre-exposure prophylaxis (‘PrEP’) medication to prevent HIV infection in people who are at high risk.
(Page 26 )
Research through partnership
This year’s achievements included care to prevent HIV infection, hope for those suffering severe asthma and dementia and a breakthrough in fighting blood cancer. We continued to attract a high level of funding from the National Health and Medical Research Council.
(Page 27)
Alzheimer’s drug trial success
Early research results of Anavex 2-73, a drug which aims to address the symptoms of dementia, are positive. Trials at Caulfield Hospital are using Anavex, which, unlike current medications, is the only drug designed to both relieve symptoms and slow the disease’s progression. The first phase of the trial began in December 2014 and the next steps will involve further research with a larger group of participants in 2017.
Thank you for clearing that up for me Investor. I’ve not had a lot of time to dig deeper recently..
Again I appreciate all of the expertise on this message board .
I am anxiously waiting for Dr. Missling to push his BIG RED BUTTON !
Investor - someone on the board wrote that clinical trials stated the purpose of the extension is
“Treatment “. I wonder if that could be the reason. The folks are just taking their daily CNS “aspirin”at home now.
Thanks for the detailed reply. I will look at it closer. Due to other infirmities I have a hard time working out but try to keep moving.I spend too much time on the computer especially with the AVXL quality message board. I am thankful for all of the experts on the board including you. I wont try to list them for fear of overlooking some. My background is electrical engineering and we certainly didn't have any biology classes. To give you an idea of how long ago that was, our education was in vacuum tubes electronics at a good engineering college.
Fireman - How long have you been on the Ketosis diet?
I have severe chronic inflammation and started to avoid all wheat and corn products products and eat mostly veggies and fruits with some meat and use Kerigold butter and coconut oil in my morning "Buttered Coffee". I try to avoid grain fed animal meats and farmed fish. This has made a big difference in my inflammation to the point that I take opioids on very rare occasions if I have eaten something to cause my problem to vigorously arise.
I have considered going completely on ketosis diet but might be difficult since I live in a retirement community and eat some meals in the
restaurants here.
SOME people have a history of posting misleading information to help drive the price up as they are selling their position off and the SAME people post misleading info to drive the price down as they are covering a short position.
I know that you are know this but I mention it in case other newer investors aren't familiar with the tactics.
Fireman-I sent you a PM so as to not clutter the message board on 4/30. I hope you give this a try also.
I know you cant send PMs (except during Friday's Happy Hour) but you can receive them. Check your mailbox if you haven't done so.